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Abstract
Background: Provision of anti-retroviral therapy (ART) for HIV-infected children is complicated using syrup formulations,
which are costlier than tablets, harder to transport and store and difficult for health-workers to prescribe and caregivers to
administer. Dispersible/crushable tablets may be more appropriate. We studied the acceptability of syrups and scored
tablets among young children who used both in the AntiRetroviral Research fOr Watoto (ARROW) trial.
Methods: ARROW is an ongoing randomized trial of paediatric ART monitoring and treatment strategies in 1206 children in
Uganda and Zimbabwe. 405 children initially received syrups of combination ART including Nevirapine, Zidovudine,
Abacavir and Lamivudine before changing, when reaching the 12-,15 kg weightband, to scored adult-dose tablets
prescribed according to WHO weightband tables. Caregiver expectations and experiences were collected in questionnaires
at their last visit on syrups and after 8 and 24 weeks on tablets.
Results: Questionnaires were completed by caregivers of 267 children (median age 2.9 years (IQR 2.5, 3.4)). At last visit on
syrups, 79% caregivers reported problems with syrups, mostly related to number, weight, transportation and
conspicuousness of bottles. Difficulties taking tablets were expected by 127(48%) caregivers; however, after 8 and 24
weeks, only 26% and 18% reported their children had problems with tablets and no problems were reported with
transportation/conspicuousness. Taste, swallowing or vomiting were reported as problems ‘sometimes/often’ for 14%, 9%,
22% children on syrups and 16%, 9%, 8% on tablets. At last visit on syrups, 74% caregivers expected to prefer tablets but
only 27% thought their child would. After 8/24 weeks, 94%/97% caregivers preferred tablets and 57%/59% reported their
child did.
Conclusions: Most children at about 3 years can take tablets; caregivers and children themselves generally prefer tablets to
liquid formulations of HIV medications above this age. Preferences of caregivers and children should be considered when
designing and licensing paediatric drug formulations.
Citation: Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, et al. (2012) Young HIV-Infected Children and Their Adult Caregivers Prefer Tablets to Syrup
Antiretroviral Medications in Africa. PLoS ONE 7(5): e36186. doi:10.1371/journal.pone.0036186
Editor: D. William Cameron, University of Ottawa, Canada
Received January 4, 2012; Accepted April 2, 2012; Published May 2, 2012
Copyright:  2012 Nahirya-Ntege et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The main trial was funded by the UK Medical Research Council, www.mrc.ac.uk and the UK Department for International Development, www.dfid.gov.
uk. Grant number G0300400. First-line drugs were provided by GlaxoSmithKline. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: First–line drugs were provided by GlaxoSmithKline. No other competing interests exist. This does not alter the authors’ adherence to all
the PLoS ONE policies on sharing data and materials.
* E-mail: adc@ctu.mrc.ac.uk
Introduction
The paediatric management of long term anti-retroviral therapy
(ART) involves interactions between children, their caregivers,
other family members and healthcare providers around adminis-
tration of antiretroviral drugs. For adults, good adherence to
medication is central to the success of ART [1,2,3]; for young
children, who rely on caregivers to administer drugs, the process is
further complicated by lower availability of simple paediatric
formulations for children of different ages [4].
In resource-limited settings, oral solution formulations present
particular challenges [5]; they are up to four times more costly
than solid formulations [6,7,8], and so for many illnesses, children
may be given reduced doses of adult formulations. Oral solutions
are also bulky, making them harder to transport and store, and are
more conspicuous than tablets which may result in problems with
confidentiality for patients receiving drugs used to treat HIV
infection [5].
Solutions and syrups are administered using syringes, and
different volumes for individual drugs are required. This, in
addition to the need to increase volume repeatedly as the child
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particularly for elderly carers who often have problems seeing
markings on syringes in the absence of glasses. Further, whereas
fixed dose formulations of anti-retroviral (ARV) drugs are
available as combination tablets [9,10,11], fixed dose combination
solutions are generally not available, so each has to be given
separately. Accurate measurement of adherence to solutions or
syrups through drug return at pharmacy level is also very
challenging, requiring weighing of bottles [12].
Major problems with the palatability of some antiretroviral oral
solutions have also been reported, in some cases requiring
administration through gastrostomy tubes [13,14,15]. To improve
palatability solutions may contain high levels of sugar; however
this may worsen dental health which has already been reported as
a problem in HIV-infected children [16].
Therefore, tablets which can be dispersed, crushed or chewed
may be preferable to solution or syrup formulations, even for very
young children, provided the correct dose can be given.
Procurement of child and adult formulations may be harmonised,
with fewer formulations required, if partial tablets can be given;
this requires tablets with active drug uniformly distributed and
scored for easy and accurate division. WHO have produced
weightband tables of preferred doses (calculated from body surface
area) of single and fixed dose combination solid formulation ARV
drugs of available doses to simplify the process of prescribing
paediatric ART by healthcare workers (Tables 1 and 2) [17].
Despite the numerous practical problems associated with
syrups, licensing authorities frequently promote the need for
liquid formulations during childhood, and there is a general lack of
data on the formulation preferences of caregivers and/or children.
In this study we evaluated the acceptability of syrup and divided
scored solid tablet formulations of antiretroviral drugs in children
weighing more than 12 kg who changed from syrups to tablet
ARV formulations. This is a substudy of the ARROW trial (www.
arrowtrial.org; ISCRTN 24791884), an ongoing randomised trial
of monitoring practice and first-line induction-maintenance ART
strategies in ART-naı ¨ve HIV-1 infected children in Uganda and
Table 1. Dosing of NRTI antiretroviral drugs in the ARROW trial using WHO weightbands based on body surface area [17].
Weight (kg) Abacavir Lamivudine Zidovudine
syrup tablets syrup tablets syrup tablets
20 mg/ml 300 mg 10 mg/ml 150 mg 10 mg/ml 300 mg
a.m. p.m a.m. p.m a.m. p.m a.m. p.m a.m. p.m a.m. p.m
5t o#7 3 ml 3 ml 3 ml 3 ml 7 ml 7 ml
7t o#10 4 ml 4 ml 4 ml 4 ml 9 ml 9 ml
10 to #12 5 ml 5 ml 5 ml 5 ml 10 ml 10 ml
12 to #15 6 ml 6 ml KK 6m l 6m l KK 12 ml 12 ml KK
15 to #17 K K KK KK
17 to #20 K K KK KK
20 to #25 1 K 1 K 1 K
25 to #30 1 1 1 1 1 K
.3 0 1 1 11 11
doi:10.1371/journal.pone.0036186.t001
Table 2. Dosing of NNRTI antiretroviral drugs in the ARROW trial using WHO weightbands based on body surface area [17].
Weight (kg) Nevirapine* Efavirenz
syrup tablets capsule capsule tablet
10 mg/ml 200 mg 50 mg 200 mg 600 mg
a.m. p.m. a.m p.m. daily daily daily
5t o#77 m l 7 m l
7t o#10 9 ml 9 ml
10 to #12 10 ml 10 ml 1
12 to #15 11 ml 11 ml KK 1
15 to #20 1 K 11
20 to #25 1 KK
25 to #30 1 1 1 K
30 to #40 1 1 2
.40 1 1 1
N Dose escalation at half dose shown for first 14 days.
doi:10.1371/journal.pone.0036186.t002
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that scored adult-dose tablets, dosed according to WHO
weightband tables, provide correct plasma ARV drug levels for
children over 3 years [18,19,20].
Methods
The study was conducted in four centres in Uganda and
Zimbabwe: the Joint Clinical Research Centre, Kampala; Baylor
College of Medicine Children’s Foundation at Mulago Hospital,
Kampala, and the Medical Research Council, Entebbe; and at the
University of Zimbabwe Clinical Research Centre, Harare. The
protocol was approved by the ethics committee local to each study
centre and by the University College London ethics committee in
the UK. All caregivers gave written informed consent.
The parent ARROW trial is an open-label randomized factorial
trial comparing two monitoring strategies and three treatment
strategies. Children were randomized to either clinically driven
monitoring (CD4 tests never returned to treating clinicians;
toxicity tests undertaken but only returned to clinicians if clinically
indicated), or laboratory plus clinical monitoring (3-monthly CD4
tests and haematology/biochemistry monitoring blood tests, all
returned to clinicians). For treatment, children were randomized
to either a continuous two nucleoside reverse transcriptase
inhibitor (NRTI) plus one non-nucleoside reverse transcriptase
inhibitor (NNRTI) regimen, or one of two induction:maintenance
regimens in which they took an additional NRTI for the first 36
weeks.
Antiretroviral drugs were supplied by ViiV GlaxoSmithKline
and national programmes as individual paediatric syrups and as
scored adult tablets (PK shown to be appropriate when
administered dispersed in water or crushed [19]) for children
.12 kg according to WHO weightband dosing tables.
Between March 2007 and November 2008, 1206 HIV-1
infected ART-naı ¨ve children aged 3 months to 17 years were
enrolled in the ARROW trial. Of these, 405 children weighed less
than 12 kg and initiated ART with syrups because parts of
individual adult tablet doses were not available for lower
weightbands [17]. On reaching 12 kg, study doctors would suggest
to caregivers that their child could now take halved scored tablets
instead of syrups with no change to dose or dosing schedule. When
caregivers were happy to change, the doctor would then prescribe
tablets. The ways in which tablets could be given, such as being
dispersed in liquids, were explained to caregivers by pharmacists;
children were not specifically coached on how to swallow tablets.
The majority of children (64%, n=171) took tablets dissolved or
crushed and administered with a small amount of liquid. After
starting tablets, care-givers were also free to change their children
back to syrups at any time.
From June 2008, acceptability questionnaires were administered
by trial nurses at the time of changing from syrups to tablets, and 8
and 24 weeks later. Nurses administering questionnaires were not
involved in the decision to change to tablets; this was made by the
caregiver with a study doctor. The initial questionnaire elicited the
caregivers’ experience with syrups and their expectations of
tablets; follow-up questionnaires asked about their actual experi-
ence with tablets. Structured questions were used to record
difficulties with syrups, problems (such as taste, swallowing,
vomiting) anticipated with tablets, problems experienced with
tablets, and the type of formulation preferred by caregivers and
their children (parents/caregivers reported their view of the
childrens’ preferences). The same questions about problems were
asked for both syrups and tablets. The questionnaires were
completed in English by nurses who asked the questions in the
local language when necessary; questionnaires were not translated
because English is widely used by both adults and children in the
urban areas of Uganda and Zimbabwe.
Statistical significance of differences between groups was
evaluated with t-tests for continuous variables and Chi-square
tests for categorical variables. Stata software, version 11.1
(StataCorp), was used in all analyses.
Results
405 children initiated ART using syrups. Of these, 63 changed
to tablets before June 2008 when the acceptability substudy began;
5 remained on syrups at the time of analysis in August 2011 (all
less than or recently attained 12 kg), and 27 had left the study
before changing formulation (20 died, 7 were lost to follow-up). Of
the 310 eligible children who changed from syrups to tablets
between June 2008 and August 2011, 21 did not have
questionnaires administered in error and 22 completed only one
questionnaire. This analysis therefore includes 267 (267/
310=86%) children who changed from syrups to tablets with
data available at the time of switch and 8 weeks later. At the time
of analysis, 91% of children changing to tablets (244/267) had
been on them for more than 24 weeks and had completed the 24-
week questionnaires.
The median age of children when they changed from syrups to
tablets was 2.9 years (IQR 2.5, 3.4), having started syrups at
median age 1.7 years (1.1, 2.3) and spent median 1.1 (0.7, 1.6)
years on ART (Table 3). Children taking tablets whole, rather
than crushed or dispersed, were slightly older (mean age 3.3 v. 2.9
years, p,0.001). Of note, no families declined to change from
syrups to tablets and the oldest child was 6 years at formulation
change. There were similar numbers of boys and girls (55% girls,
n=146). At ART initiation, severe wasting and stunting were
common (weight-for-age Z-score median 23.1, IQR 24.4,22.1;
Table 3. Participant characteristics, 267 children.
At start of syrups At change to tablets
Median IQR Median IQR
Age (years) 1.7 (1.1, 2.3) 2.9 (2.5, 3.4)
Sex, n (%) male 121 (45%)
Weight-for-age Z score 23.1 (24.4, 22.1) 21.2 (21.8, 20.5)
Height-for-age Z score 23.1 (24.1, 22.2) 22.7 (23.2, 21.7)
CD4% 13.6% (10%, 19%) 32% (26%, 38%)
WHO stage 3, n(%) 134 (50%)
WHO stage 4, n(%) 66 (25%)
Person bringing child,
n(%)
Mother 197 (74%)
Father 16 (6%)
Grandmother 28 (10%)
Aunt 17 (6%)
Other 9 (4%)
doi:10.1371/journal.pone.0036186.t003
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ART considerable recovery had occurred before changing to
tablets (Table 3). Similarly, most children were moderate to
severely immuno-compromised at the time of ART initiation (pre-
ART CD4% median 13.6% (IQR 10%,19%); CD4 count median
794 (516,1184)), but substantial increases had occurred on ART
before changing to tablets (at change to tablets CD4% median
32% (26%, 38%); CD4 count median 1409 cells/mm3 (975,
2078)). Most children had quite advanced HIV disease at ART
initiation; 50% (n=134) and 25% (n=66) had experienced WHO
stage 3 and stage 4 events respectively.
Caregiver expectation of tablets
Before changing formulation, approximately half the caregivers
expected to encounter difficulties administering tablets to their
children (48%, n=127), in particular because of taste (30%,
n=80), swallowing (25%, n=66) or vomiting (19%, n=51) which
they expected might be difficult with tablets. Problems were
anticipated slightly more frequently by those who reported
problems while giving syrups, but the difference between groups
was not statistically significant (50%, n=105 of those reporting
problems with syrups expected problems with tablets v. 40%,
n=22 among others, p=0.21).
Experience with syrups
At the time of changing from syrup to tablet formulations, 212
(79%) primary caregivers reported they had experienced problems
either sometimes or often while using syrups. Most difficulties
related to managing the large number of bottles supplied by the
pharmacy (reported by 47%, n=123), the weight of bottles (63%,
n=166), and transporting bottles (58%, n=152) (Table 4). A child
on three-drug ART weighing 10–12 kg would typically require
seven bottles of syrup at each 28-day visit and therefore
considerably more with less frequent visits. Anecdotally, clinic
staff had noticed caregivers bringing increasingly large bags to
clinics in order to carry syrups home.
Experience with tablets
After 8 weeks of administering tablets, 69 (26%) caregivers
reported problems, declining to 45 (18%) after 24 weeks. The most
frequently reported difficulties decreased between 8 and 24 weeks:
from 16% to 13% for tablet taste, 9% to 5% for swallowing
difficulties, and 8% to 7% for vomiting. At 8 weeks, only problems
with taste were reported more frequently with tablets than with
syrups and this reversed by week 24 (Figure 1). Problems during
the first 8 weeks of tablets were no more likely to occur among
children previously having problems with syrups (Table 5);
however 21% (n=41) of those with problems continuing at 24
weeks had experienced problems with syrup, compared to 8%
(n=4) among those not having problems with syrups (p=0.04).
Overall preference
Before using tablets, caregiver opinion was divided about which
formulation they thought their child would prefer (27% tablets,
29% syrups, 44% no preference (Figure 2). However, after 8 weeks
on tablets, more than half the caregivers reported a preference
among their children for tablets (57% tablets, 9% syrups, 34% no
preference), with a similar preference at 24 weeks (59% tablets, 6%
syrups, 35% no preference). The age of the 23 children who
preferred syrups after 8 weeks using tablets was similar to the 151
children reported to prefer tablets (mean age 2.9 v. 3.1 years,
p=0.20); however, all those preferring syrups were less than 4
years of age. Of note, no child changed from tablets back to liquids
during the 24 weeks follow-up.
When asked about preference from their own (as opposed to
their child’s) perspective, caregivers questioned before formulation
Table 4. Problems experienced sometimes or often: using syrups; first 8 weeks of tablets; first 24 weeks of tablets.
Syrups, n=267 Tablets, n=267 (8 wks) Tablets, n=244 (24 wks)
n (%) N n (%) N n (%) N
Timing of dose 23 (8.6) 267 4 (1.5) 263 5 (2.0) 244
Measuring syrup/Counting
tablets
24 (9.0) 267 2 (0.7) 265 2 (0.8) 244
Taste 38 (14.3) 266 42 (15.7) 225 31 (12.7) 244
Swallowing 25 (9.4) 265 24 (9.0) 243 11 (4.5) 243
Vomiting 58 (22.0) 264 22 (8.4) 239 17 (7.0) 242
Taking the whole dose 10 (3.8) 264 5 (1.9) 256 8 (3.3) 242
Storage 21 (8.0) 263 0 (0.0) 261 1 (0.4) 242
Number of bottles 123 (46.8) 263 0 (0.0) 261 2 (0.8) 242
Weight of bottles 166 (63.1) 263 1 (0.4) 260 2 (0.8) 242
Transporting bottles 152 (57.6) 264 0 (0.0) 261 2 (0.8) 242
Losing/breaking bottles 24 (9.1) 264 0 (0.0) 261 1 (0.4) 242
Identifying different drug
bottles
11 (4.2) 264 4 (1.5) 257 2 (0.8) 242
Keeping syrup cool 3 (1.1) 262 N/A N/A
Conspicuousness 33 (12.5) 264 3 (1.1) 258 3 (1.2) 242
Cleaning the syringes 26 (9.8) 264 N/A N/A
Losing the syringes 8 (3.0) 264 N/A N/A
Opening tablet bottles N/A 3 (1.1) 258 1 (0.4) 242
doi:10.1371/journal.pone.0036186.t004
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(74% tablets, 13% syrups, 13% no preference). After 8 weeks on
tablets, actual preference increased for tablets (94% tablets, 3%
syrups, 3% no preference), and after 24 weeks nearly all caregivers
preferred tablets (97% tablets, 1% syrups, 2% no preference).
Discussion
There are few studies comparing the acceptability of tablet and
syrup formulations of drugs for caregivers and their children; for
antiretroviral drugs, this is particularly important because treat-
ment is life-long and adherence is critical for successful outcome.
In our study of young children in a resource-limited setting, we
report a preference for tablets, which increased with time from
starting tablets. Since children were young at the time of changing
from syrups to tablets (around 3 years of age), we asked caregivers
about the preference of their children, and also their own
preference as caregivers. We found that most children, at about
3 years, can take tablets and that caregivers and children
themselves generally prefer tablets to liquid formulations of HIV
medications above this age.
In a small qualitative study, also in the field of HIV infection,
Bagenda et al. [21] reported that caregivers preferred giving their
children tablets rather than syrups. Reasons for disliking syrups
were problems with measurement, spillage and the bulkiness of
single drug formulations, very similar to the practical problems
reported by caregivers in our study. In a larger quantitative study
the same authors reported significantly better adherence using
tablets instead of syrups [22], based on pharmacy refill data. A
study by Yeung et al. [23] found that HIV-infected children
changed formulation at around 7 years in the UK; one would
expect the acceptability of tablets to increase with age during
childhood but the narrow ageband (IQR 2 to 3 years) made this
difficult to assess in our study. Preferences and acceptability were
not formally or prospectively evaluated in the UK study and it can
only be assumed, as children were switched to ‘off label’ adult
formulations (which would not then have been licensed for
children and may not have been scored), that this was undertaken
in consultation with caregivers and it may have been driven by
children or carers experiencing problems taking syrups.
Pill swallowing skills can be learned by children at relatively
young ages. Garvie et al reported that US children as young as 4
Figure 1. Problems ‘sometimes’ or ‘often’ with syrups and tablets.
doi:10.1371/journal.pone.0036186.g001
Table 5. Problems after 8 and 24 weeks on tablets, by problems with syrups.
8 weeks of tablets 24 weeks of tablets
Syrup problem no problem N p Syrup problem no problem N p
problem 51 (26%) 144 (74%) 195 problem 41 (21%) 154 (79%) 195
no problem 13 (27%) 36 (73%) 49 0.96 no problem 4 (8%) 45 (92%) 49 0.04
N 64 180 244 N 45 199 244
244 children with 8 and 24 week questionnaires.
doi:10.1371/journal.pone.0036186.t005
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concerns and expectations [24], while Thomson et al reported
increasing ability to swallow minitablets with age in children aged
2 to 5 years [25]. The narrow ageband of children in this study
prevented analysis of swallowing technique and age; however most
caregivers crushed or dispersed tablets in a small amount of liquid.
Of note, the package insert did not formally state that drugs were
dispersible, but this was demonstrated by study investigators before
the study commenced, and pharmacokinetic data were satisfactory
when administering drugs this way to the same children [19].
Taste, swallowing and vomiting were the key difficulties expected
by the caregivers of children changing to tablets; however, these
difficulties appeared no worse for tablets than they had been for
syrups and by 24 weeks on tablets few problems were reported,
and these were mainly in children who had also had problems with
syrups. For 14 children the change from syrups to tablets coincided
with the planned reduction from 4 to 3 drugs in their
induction:maintenance regimen; while their preference for tablets
may have been inflated by this change, any impact on overall
results is likely to be small. The strength of the preference for
tablets is perhaps best informed by the fact that no child in this
study changed from tablets back to syrups, although this option
was available. Syrup formulations used in this study did not
require refrigeration; it seems likely that this would have further
strengthened the preference for tablets, a further consideration
with increasing use of first-line protease inhibitors where syrups
need refrigeration.
Reasons for caregivers preferring tablets appeared to relate
mainly to practical issues such as transportation and conspicuous-
ness in the household, as recognition of antiretroviral drugs could
be associated with HIV infection. In general, the proportion of
caregivers who preferred tablets was consistently higher than the
proportion who said their children preferred them. As caregivers
were reporting for their children, it is possible that caregivers’
preference for tablets could have influenced their reporting of
specific child-related problems in favour of tablets.
Young HIV-infected children starting ART depend on adults
for their care and adherence to medication. Bagenda et al reported
that the biggest challenge felt by caregivers was the commitment to
administering lifelong ART [21]. The difficulties faced by
caregivers while using liquid formulations should therefore be
considered alongside the perceived preferences of the children
themselves. If caregivers’ experience of giving ART can be
improved by moving children to tablets at an early age, this could
improve adherence and thus efficacy. However, we are unaware of
any trials comparing outcomes of randomising children to
continue liquid formulations or to move to solid-based formula-
tions. In ARROW we are collecting adherence data on both
syrups and tablets, although direct comparison may be limited by
differences in data collection methods. This highlights another
problem with the use of liquid formulations in resource-limited
settings as the weighing of bottles is time-consuming, requires
complex calculations and is likely to be subject to greater error
than pill counts. Further, prescribing exact amounts of syrup
required between each visit is more difficult than using tablets.
The simplification and standardisation of ART is an essential
feature of HIV treatment scale up and rollout to lower level health
centres in rural areas where large numbers of people with HIV
live. In fact, the WHO promotes Flexible Solid Oral Dosage forms
(FSOD) as part of it’s ‘Make Medicines Child Size’ initiative; these
are dosage forms that can be swallowed whole or split, or can be
dispersed in liquid prior to administration. Wherever possible,
formulations of new HIV drugs with potential for use in children
should be scored, (although, of note, WHO recommends no more
than a single scoreline for HIV drugs to produce 2 equal halves as
‘‘quarters’’ scoring is likely to be impractical and result in errors).
The WHO weightband dosing tables were designed to be used
across all anti-retroviral drugs, with the dose of each drug fixed
(e.g. K tablet am/pm) for any given weightband, thus reducing
the complexity of prescribing for healthworkers, as well as
administration by caregivers as all drug doses change at the same
time. Weightband doses for the NRTI drugs were calculated using
the licensed recommendations for whole or half adult tablets made
by ViiV Glaxosmithkline, validated by pharmacokinetic studies
[18,19,20], and which have been licensed by EMA in Europe and
FDA in US. Dosing of tablets using such weightband tables
Figure 2. Overall preference for syrups and tablets.
doi:10.1371/journal.pone.0036186.g002
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are calculated using mg per kg for some drugs (eg abacavir or
lamivudine) and mg per m
2 body surface area for others
(zidovudine), which is more likely to be associated with dosing
errors [26]. Affordable fixed-dose combination (FDC) solid scored
tablets of several antiretroviral drugs are also now available and
licensed for children, and provide an even easier way for
caregivers to administer and health workers to prescribe ARVs
[17,27,28].
Liquid formulations may be needed for treatment of infants,
although some ‘baby’ FDCs can be given to infants as small as
3 kg. Our large study provides evidence to challenge those
advocating for syrup formulations beyond age 3 years. Organisa-
tions such as the Drugs for Neglected Diseases initiative (DNDi),
Medecins sans Frontieres (MSF) and the United Nations Childrens
Fund (UNICEF) are all working on the development of closer links
between pharmaceutical companies, regulators, paediatricians and
families to promote more timely development of appropriate
paediatric formulations and better harmonisation between formu-
lation needs of children and adults in order to simplify supply
chain logistics for implementers of ARV programmes. Thus, drug
manufacturers (both innovator and generic) should be encouraged
to formally address issues which might impact on successful
scoring early in development. These include the content unifor-
mity (to allow pills to be split), pharmacokinetic characteristics
(Cmax, Cmin and AUC) when tablets are taken whole or when
split (i.e. supportive formal PK studies to demonstrate bioequiv-
alence), and dispersiblity in water.
In summary, scored tablets of ARVs for children as young as
three years cause few problems and most children and almost all
caregivers prefer them. The high acceptability of the tablets by
caregivers may help adherence thereby improving efficacy and
durability of treatment among young children who face life-long
ART. In addition, tablets can reduce logistic problems for health
system providers, simplify prescribing for healthcare workers and
reduce the burden of care for caregivers. We would argue that
scoring adult tablets so they can be easily and accurately broken
should be considered at an early stage in drug development if it is
anticipated that children will also benefit; this might also reduce
the time taken for drugs to be licensed for use in children.
Preferences of caregivers and their children should be considered
when designing and licensing paediatric drug formulations,
particularly for resource-limited settings where most HIV-infected
children live.
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